Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company’s experimental psilocybin treatment for a form of hard-to-treat depression produced results that, while technically successful, fell short of investor expectations.The late-stage trial tested a synthesized version of psilocybin—the psychoactive compound in magic…
Japan’s rice prices are facing their most severe shock in more than half a century, with costs more than…
According to a report from the German publication Spiegel, Audi is considering plans to build a new factory in the…
Bank of America Global Research boosted its year-end projection for the STOXX 600 index to 530 from 500 on…
Palantir co-founder and renowned defense investor Joe Lonsdale weighed in on escalating tensions between Israel and Iran in a…
Tesla has signed its first agreement to build a utility-scale battery storage facility in China, marking a major step…
Autonomous vehicles have already started taking share within ride-sharing and trucking industries this year, and Goldman Sachs believes the…
Investors have bailed on First Solar Inc (NASDAQ: FSLR) in recent sessions after the US Senate backed removal of…
Seaborne loadings of gasoline and blending components in the Atlantic Basin are experiencing rapid growth.The brief period in May,…